Li, Meng

Publications

Sort by

Co-Author Network

A Mitochondria-Targeting SIRT3 Inhibitor with Activity against Diffuse Large B Cell Lymphoma. Journal of medicinal chemistry. 2024 Academic Article GET IT
Multilayered Immunity by Tissue-Resident Lymphocytes in Cancer. Annual review of immunology. 2024 Review GET IT
Multi-omic Analysis of Human B-cell Activation Reveals a Key Lysosomal BCAT1 Role in mTOR Hyperactivation by B-cell receptor and TLR9. 2024 GET IT
Simultaneous inhibition of Sirtuin 3 and cholesterol homeostasis targets acute myeloid leukemia stem cells by perturbing fatty acid β-oxidation and inducing lipotoxicity. Haematologica. 2023 Academic Article GET IT
Translational Activation of ATF4 through Mitochondrial Anaplerotic Metabolic Pathways Is Required for DLBCL Growth and Survival. Blood cancer discovery. 2021 Academic Article GET IT
Non-oncogene Addiction to SIRT5 in Acute Myeloid Leukemia. Blood cancer discovery. 2021 Comment GET IT
Chemotherapy Induces Senescence-Like Resilient Cells Capable of Initiating AML Recurrence. Cancer discovery. 2021 Academic Article GET IT
Times cited: 136
Non-oncogene Addiction to SIRT3 Plays a Critical Role in Lymphomagenesis. Cancer cell. 2019 Academic Article GET IT
Times cited: 84
Rational Targeting of Cooperating Layers of the Epigenome Yields Enhanced Therapeutic Efficacy against AML. Cancer discovery. 2019 Academic Article GET IT
Times cited: 34

Sort by

Co-investigator Network

Therapeutic Targeting of SIRT3 for Aggressive and Refractory Lymphomas awarded by National Cancer Institute Co-Investigator 2023 - 2028